Healthcare provider profile · identity verified

Thea E Petersen, MD

Allopathic & Osteopathic Physicians|Family Medicine · COTTAGE GROVE, OR · NPI 1083887087

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Thea E Petersen, MD received $111.36 in general payments during 2025 across 1 reported records.

Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$111.36

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$111.36	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$111.36	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	154	27
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	562	166
Losartan Potassium	Losartan Potassium	423	120
Levothyroxine Sodium	Levothyroxine Sodium	363	86
Lisinopril	Lisinopril	310	88
Amlodipine Besylate	Amlodipine Besylate	300	85
Omeprazole	Omeprazole	260	76
Metformin Hcl Er	Metformin Hcl	224	70
Eliquis	Apixaban	206	34
Gabapentin	Gabapentin	202	53
Metoprolol Succinate	Metoprolol Succinate	168	49
Jardiance	Empagliflozin	157	39
Ozempic	Semaglutide	154	27
Albuterol Sulfate Hfa	Albuterol Sulfate	148	65
Trazodone Hcl	Trazodone Hcl	144	35
Duloxetine Hcl	Duloxetine Hcl	142	45
Alendronate Sodium	Alendronate Sodium	133	47
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	133	30
Bupropion Xl	Bupropion Hcl	130	39
Hydrochlorothiazide	Hydrochlorothiazide	117	38
Pravastatin Sodium	Pravastatin Sodium	111	34
Tramadol Hcl	Tramadol Hcl	110	18
Metoprolol Tartrate	Metoprolol Tartrate	105	33
Spironolactone	Spironolactone	104	34
Pantoprazole Sodium	Pantoprazole Sodium	95	25
Rosuvastatin Calcium	Rosuvastatin Calcium	95	30
Tamsulosin Hcl	Tamsulosin Hcl	93	23
Simvastatin	Simvastatin	91	25
Furosemide	Furosemide	88	30
Carvedilol	Carvedilol	87	25
Montelukast Sodium	Montelukast Sodium	80	21
Potassium Chloride	Potassium Chloride	78	31
Sertraline Hcl	Sertraline Hcl	75	18
Baclofen	Baclofen	74	20
Tizanidine Hcl	Tizanidine Hcl	74	28
Famotidine	Famotidine	69	17
Fluoxetine Hcl	Fluoxetine Hcl	67	18
Meloxicam	Meloxicam	64	24
Oxycodone Hcl	Oxycodone Hcl	64	19
Ondansetron Odt	Ondansetron	62	19
Fluticasone Propionate	Fluticasone Propionate	57	30
Warfarin Sodium	Warfarin Sodium	56	13
Zolpidem Tartrate	Zolpidem Tartrate	56	16
Estradiol	Estradiol	54	33
Triamcinolone Acetonide	Triamcinolone Acetonide	54	40
Lovastatin	Lovastatin	51	16
Buspirone Hcl	Buspirone Hcl	50	15
Citalopram Hbr	Citalopram Hydrobromide	49	16
Quetiapine Fumarate	Quetiapine Fumarate	48	suppressed
Glimepiride	Glimepiride	47	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	47	12
Venlafaxine Hcl Er	Venlafaxine Hcl	47	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	44	15
Metformin Hcl	Metformin Hcl	43	14
Clonazepam	Clonazepam	41	suppressed
Prednisone	Prednisone	41	23
Topiramate	Topiramate	41	11
Propranolol Hcl	Propranolol Hcl	40	16
Olmesartan Medoxomil	Olmesartan Medoxomil	38	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	36	suppressed
Trulicity	Dulaglutide	36	suppressed
Ezetimibe	Ezetimibe	35	14
Escitalopram Oxalate	Escitalopram Oxalate	34	11
Sumatriptan Succinate	Sumatriptan Succinate	34	suppressed
Allopurinol	Allopurinol	33	11
Clonidine Hcl	Clonidine Hcl	33	suppressed
Mirtazapine	Mirtazapine	31	14
Pregabalin	Pregabalin	31	13
Solifenacin Succinate	Solifenacin Succinate	29	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	28	suppressed
Clopidogrel	Clopidogrel Bisulfate	28	suppressed
Enalapril Maleate	Enalapril Maleate	27	suppressed
Acyclovir	Acyclovir	26	suppressed
Finasteride	Finasteride	26	suppressed
Mounjaro	Tirzepatide	26	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	23	suppressed
Ibuprofen	Ibuprofen	23	suppressed
Lamotrigine	Lamotrigine	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Propranolol Hcl Er	Propranolol Hcl	22	suppressed
Torsemide	Torsemide	22	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	21	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	12
Hydroxyzine Hcl	Hydroxyzine Hcl	21	13
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	19	suppressed
Loperamide	Loperamide Hcl	19	suppressed
Lorazepam	Lorazepam	19	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Tresiba Flextouch U-200	Insulin Degludec	19	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Irbesartan	Irbesartan	18	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Nystatin	Nystatin	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Divalproex Sodium	Divalproex Sodium	16	suppressed
Entresto	Sacubitril/Valsartan	16	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	16	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Butalb-Acetaminoph-Caff-Codein	Butalbit/Acetamin/Caff/Codeine	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Ranolazine Er	Ranolazine	14	suppressed
Rybelsus	Semaglutide	14	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	13	suppressed
Morphine Sulfate	Morphine Sulfate	13	suppressed
Valsartan	Valsartan	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Buprenorphine Hcl	Buprenorphine Hcl	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Nabumetone	Nabumetone	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Temazepam	Temazepam	12	suppressed
Testosterone Cypionate	Testosterone Cypionate	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Guanfacine Hcl	Guanfacine Hcl	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Lactulose	Lactulose	11	suppressed
Liothyronine Sodium	Liothyronine Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$111.36 · 1 records	Novo Nordisk Inc	—	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error